Comorbidity and survival of Danish cirrhosis patients: a nationwide population-based cohort study

Peter Jepsen1, Hendrik Vilstrup, Per Kragh Andersen

  • 1Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark. pj@dce.au.dk

Insights

Comorbidities significantly increase mortality risk in liver cirrhosis patients. Treating these co-existing conditions in the first year after diagnosis can substantially lower death rates.

Area of Science:

  • Hepatology
  • Internal Medicine
  • Public Health

Background:

  • Liver cirrhosis patients face high mortality from both cirrhosis and other causes.
  • The prognostic impact of comorbidities in cirrhosis patients remains under-examined.

Purpose of the Study:

  • To investigate the prognostic impact of comorbidity burden on mortality in liver cirrhosis patients.
  • To analyze the risks of cirrhosis-related and non-cirrhosis-related death in relation to comorbidity.

Main Methods:

  • Utilized a nationwide Danish hospital registry (1995-2006) to identify 14,976 cirrhosis patients.
  • Calculated comorbidity burden using the Charlson Comorbidity Index.
  • Compared survival and mortality risks, adjusting for covariates and using a matched comparison cohort.

Main Results:

  • 38% of cirrhosis patients had at least one comorbidity.
  • Mortality rates increased with higher Charlson Comorbidity Index scores (e.g., 2-fold increase for index ≥3).
  • Comorbidity elevated the risk of cirrhosis-related death in the first year post-diagnosis.

Conclusions:

  • Comorbidity is a significant prognostic factor in liver cirrhosis.
  • Effective management of comorbid diseases within the first year of cirrhosis diagnosis may improve survival rates.
Abstract

Related Concept Videos

Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...
Cirrhosis I: Introduction01:23

Cirrhosis I: Introduction

Cirrhosis is a chronic, irreversible liver disease characterized by the widespread replacement of healthy liver tissue with fibrotic scar tissue and the formation of regenerative nodules.Etiology of cirrhosisCirrhosis results from sustained liver injury that triggers progressive fibrosis and structural remodeling. The underlying causes are diverse, encompassing common and less frequent clinical conditions. Regardless of the origin, all causes lead to chronic inflammation, hepatocyte loss, and...
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Cancer Survival Analysis01:21

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not related to...
Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol abuse, or...